JP2001521486A - 改良リポソーム組成物を製造するための材料および方法 - Google Patents

改良リポソーム組成物を製造するための材料および方法

Info

Publication number
JP2001521486A
JP2001521486A JP53466097A JP53466097A JP2001521486A JP 2001521486 A JP2001521486 A JP 2001521486A JP 53466097 A JP53466097 A JP 53466097A JP 53466097 A JP53466097 A JP 53466097A JP 2001521486 A JP2001521486 A JP 2001521486A
Authority
JP
Japan
Prior art keywords
liposome
vip
biologically active
peptide
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53466097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001521486A5 (https=
Inventor
オンユクセル，ハヤット
ルービンスタイン，イスラエル
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ filed Critical ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ
Publication of JP2001521486A publication Critical patent/JP2001521486A/ja
Publication of JP2001521486A5 publication Critical patent/JP2001521486A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP53466097A 1996-03-28 1997-03-28 改良リポソーム組成物を製造するための材料および方法 Pending JP2001521486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1436396P 1996-03-28 1996-03-28
US60/014,363 1996-03-28
PCT/US1997/005161 WO1997035561A1 (en) 1996-03-28 1997-03-28 Materials and methods for making improved liposome compositions

Publications (2)

Publication Number Publication Date
JP2001521486A true JP2001521486A (ja) 2001-11-06
JP2001521486A5 JP2001521486A5 (https=) 2004-12-02

Family

ID=21765043

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53466097A Pending JP2001521486A (ja) 1996-03-28 1997-03-28 改良リポソーム組成物を製造するための材料および方法

Country Status (6)

Country Link
US (2) US6197333B1 (https=)
EP (1) EP0914094A4 (https=)
JP (1) JP2001521486A (https=)
AU (2) AU2549297A (https=)
CA (1) CA2250219C (https=)
WO (2) WO1997035561A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535349A (ja) * 1999-01-27 2002-10-22 ザ、ボード、オブ、トラスティーズ、オブ、ザ、ユニバシティー、オブ、イリノイ 改良されたミセル組成物を生成するための材料および方法
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
JP2005170928A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
JP2005289859A (ja) * 2004-03-31 2005-10-20 Konica Minolta Medical & Graphic Inc Ｘ線ｃｔ用造影組成物およびその製造方法

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US20050025819A1 (en) * 1997-07-14 2005-02-03 Hayat Onyuksel Materials and methods for making improved micelle compositions
EP1030652B1 (en) 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
DE19813773A1 (de) * 1998-03-27 1999-09-30 Clemens Unger Verfahren zur Herstellung von liposomalen Wirkstoffformulierungen
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20020114829A1 (en) * 1998-12-18 2002-08-22 Hayat Onyuksel Materials and methods for making improved liposome compositions
EP1180242A1 (de) * 1999-05-27 2002-02-20 Zeptosens AG Polymer-enthaltendes vesikel und darauf basierte sensor-nachweisverfahren
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
AU2002220720B2 (en) 2000-11-28 2006-09-14 Mondobiotech Ag Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US6534080B2 (en) 2001-02-12 2003-03-18 Super Gen, Inc. Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin
US6509027B2 (en) 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US6497896B2 (en) 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
WO2003068941A2 (en) 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US20040005351A1 (en) * 2002-03-29 2004-01-08 Kwon Glen S. Polymeric micelle formulations of hydrophobic compounds and methods
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
CA2488358A1 (en) 2002-06-10 2003-12-18 Mondobiotech Laboratories Anstalt Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
US7785623B2 (en) * 2002-10-01 2010-08-31 Keller Brian C Compositions and methods useful for the reduction of fine lines and wrinkles
CA2509755A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US8846079B1 (en) 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20060251711A1 (en) * 2003-08-28 2006-11-09 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US6911430B2 (en) * 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
US6998028B1 (en) * 2004-09-24 2006-02-14 Superpower, Inc. Methods for forming superconducting conductors
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) * 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
CA2748995C (en) * 2008-10-07 2018-01-16 Bracco Suisse Sa Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
EP2184054A1 (en) * 2008-11-08 2010-05-12 Lipoxen Technologies Limited Small Interfering RNA Delivery
US20110158903A1 (en) * 2009-12-31 2011-06-30 Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan One pot processes of preparing multifunctional liposome drug for imaging, delivery and targeting in cancer diagnosis and therapy
EP2704688B1 (en) * 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
CA2902565C (en) 2013-03-15 2022-11-29 Loma Linda University Treatment of autoimmune diseases
US9987227B2 (en) 2013-10-22 2018-06-05 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
US10765817B2 (en) 2014-08-13 2020-09-08 Elwha, Llc Methods, systems, and devices related to delivery of alcohol with an inhaler
US10987048B2 (en) 2014-08-13 2021-04-27 Elwha Llc Systems, methods, and devices to incentivize inhaler use
US10245393B2 (en) 2014-08-13 2019-04-02 Elwha Llc Methods, systems, and devices related to a supplemental inhaler
EP3349729A4 (en) 2015-09-14 2019-06-26 VGSK Technologies, Inc. STERILE-STABILIZED CARRIER FOR SUBCUTANEOUS, SUB-LINGUAL AND ORAL THERAPEUTICS, COMPOSITIONS AND METHOD FOR TREATING ANIMALS
US9836646B2 (en) * 2015-10-15 2017-12-05 I.R.I.S. Method for identifying a character in a digital image
EP3538546B1 (en) 2016-11-14 2025-01-08 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019213398A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
US12319967B2 (en) 2019-08-21 2025-06-03 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
EP4232605A4 (en) 2020-11-11 2024-09-25 University of Virginia Patent Foundation METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NON-CODING RNA OVERLAPPING THE LCK GENE REGULATING PROSTATE CANCER CELL GROWTH
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2022235907A1 (en) 2021-05-05 2022-11-10 Vgsk Technologies, Inc. Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation
GB2627096A (en) 2021-10-14 2024-08-14 Pacira Pharmaceuticals Inc Bupivacaine multivesicular liposome formulations and uses thereof
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529561A (en) * 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
JPS5782311A (en) * 1980-11-11 1982-05-22 Tanabe Seiyaku Co Ltd Production of liposome preparation
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
ZA896668B (en) 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
WO1993020802A1 (en) 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
ATE163230T1 (de) 1993-03-09 1998-02-15 Epic Therapeutics Inc Makromolekulare mikropartikel und verfahren zu ihrer herstellung
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5534241A (en) 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
EP0759768A4 (en) * 1994-04-07 2000-08-09 Proteinix Company VASOACTIVE COLON PEPTIDE
US5567410A (en) 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging
US5587149A (en) 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535349A (ja) * 1999-01-27 2002-10-22 ザ、ボード、オブ、トラスティーズ、オブ、ザ、ユニバシティー、オブ、イリノイ 改良されたミセル組成物を生成するための材料および方法
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
JP2005170928A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
JP2005289859A (ja) * 2004-03-31 2005-10-20 Konica Minolta Medical & Graphic Inc Ｘ線ｃｔ用造影組成物およびその製造方法

Also Published As

Publication number Publication date
CA2250219C (en) 2008-10-07
CA2250219A1 (en) 1997-10-02
AU2426197A (en) 1997-10-17
EP0914094A4 (en) 2000-03-01
US6348214B1 (en) 2002-02-19
US6197333B1 (en) 2001-03-06
WO1997035560A1 (en) 1997-10-02
AU733212B2 (en) 2001-05-10
AU2549297A (en) 1997-10-17
WO1997035561A1 (en) 1997-10-02
EP0914094A1 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
JP2001521486A (ja) 改良リポソーム組成物を製造するための材料および方法
US5612057A (en) Acoustically reflective liposomes and methods to make and use same
US5858399A (en) Acoustically reflective liposomes and methods to make and use the same
DE69925461T2 (de) Zielgerichtete abgabe von biologische-aktive medien
Huang et al. Acoustically active liposomes for drug encapsulation and ultrasound-triggered release
CA2355269C (en) Materials and methods for making improved micelle compositions
WO2019141271A1 (zh) 用于靶向活化cd44分子的脂质体纳米载体递送系统、其制备方法和用途
EP2730277A2 (en) Drug carrier and drug carrier kit for inhibiting fibrosis
US20080160074A1 (en) Pharmaceutically acceptable phosphate-glycerol carrying bodies
EP2680822B1 (en) Vesicle compositions
US20020114829A1 (en) Materials and methods for making improved liposome compositions
Séjourné et al. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes
KR20150078952A (ko) 활성 성분 및 조영제를 포함하는 리포좀 및 그의 용도
US20050058697A1 (en) Cell penetrating therapeutic agents
CN117159469A (zh) 一种靶向性脂质体纳米药物及其制备方法和应用
JP6903318B2 (ja) 一酸化窒素内包バブルリポソーム及びその利用
JP4997486B2 (ja) 脈管障害部位集積性担体
JP2006514924A (ja) 走触性ペプチドを含むリポソーム組成物及びその使用
Önyüksel et al. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity
Vashisth et al. A COMPREHENSIVE REVIEW ABOUT THE DEVELOPMENT, CHARACTERIZATION AND SKIN DELIVERY STUDIES OF ULTRADEFORMABLE VESICLES: TRANSFERSOMES
Séjourné et al. Development of a Novel Bioactive
US20080075764A1 (en) Pharmaceutically acceptable phosphate-glycerol carrying bodies
Thong Effect of formulation variables on insulin localisation within solid lipid nanoparticles
US20080171082A1 (en) Pharmaceutically acceptable phosphate-glycerol carrying bodies
AU2003201569A1 (en) Pharmaceutically acceptable phosphate-glycerol carrying bodies

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20040223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091208